Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT04699188

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Sponsor: Novartis Pharmaceuticals

Conditions Cancer of Lung Cancer of the Lung Carcinoma, Colorectal Carcinoma, Non-Small-Cell Lung KRAS G12C Mutant Solid Tumors Lung Cancer Neoplasms, Lung Neoplasms, Pulmonary Pulmonary Cancer Pulmonary Neoplasms

Interventions JDQ443 TNO155 tislelizumab

Updated 34 times since 2021 Last updated: Mar 9, 2026 Started: Feb 24, 2021 Primary completion: Aug 20, 2026 Completion: Aug 20, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Cancer of Lung and Cancer of the Lung and is currently ongoing. Novartis Pharmaceuticals leads this study, which shows 34 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

34 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2025 — Mar 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Apr 2025 — Jul 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jan 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

▶ Show 29 earlier versions

Dec 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
May 2024 — Jun 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1_PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2
Mar 2023 — May 2023 [monthly]

Recruiting PHASE1_PHASE2
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
Nov 2022 — Feb 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE1_PHASE2
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
Apr 2022 — Jun 2022 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE1_PHASE2
Oct 2021 — Feb 2022 [monthly]

Recruiting PHASE1_PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE1_PHASE2
May 2021 — Jun 2021 [monthly]

Recruiting PHASE1_PHASE2
Apr 2021 — May 2021 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2021 — Apr 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Atlanta, United States , Barcelona, Spain , Beijing, China , Boston, United States , Brescia, Italy , Chuo Ku, Japan , Cologne, Germany , Copenhagen, Denmark , Dresden, Germany and 25 more locations